Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | BACE1 | P56817 | 4/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260091 | 0.84 | PRMT6 (0.49) | BCHEBACE1CARM1PRMT6KDM4E | |
| SCHEMBL13918962 | 0.83 | BCHE (0.54) | BCHEBACE1SCN8AKMT2AMEN1 | |
| SCHEMBL2912654 | 0.81 | TAAR1 (0.58) | BCHEBACE1CHRM2KDM4ECYP1A2 | |
| SCHEMBL17664610 | 0.81 | BCHE (0.51) | BCHEBACE1SCN8ACYP1A2CYP2D6 | |
| SCHEMBL13253641 | 0.81 | MEN1 (0.47) | CARM1PRMT6KMT2AMEN1TDP1 | |
| SCHEMBL18232504 | 0.81 | MC4R (0.53) | BCHEBACE1SCN8ACHRM2KDM4E | |
| SCHEMBL13154916 | 0.81 | BCHE (0.49) | BCHEBACE1SCN8AKMT2AMEN1 | |
| SCHEMBL13166761 | 0.81 | BCHE (0.49) | BCHEBACE1SCN8AKMT2AMEN1 | |
| SCHEMBL13168316 | 0.79 | CA1 (0.53) | KMT2AMEN1TDP1KDM4E | |
| SCHEMBL7813797 | 0.77 | MEN1 (0.47) | CARM1PRMT6KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | BCHE 4787/4885BACE1 1760/4885SCN8A 4608/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | BCHE 4768/4885BACE1 1608/4885SCN8A 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.